754 / 1082
S738
ESTRO 36 2017
_______________________________________________________________________________________________
bone/soft-tissue/lymph-nodes was 46% (median survival
time, 11 months), while that was 15% for the patients who
received PRIT to other organs (median survival time, 4
months).
Conclusion
With regard to patients with good performance status,
prognosis of patients who received PIRT to bone/soft-
tissue or lymph-nodes was comparatively good. Despite
small patient number of this study, it seemed that
extremely hypofractionated PIRT was not suitable for
these patients.
EP-1395 CyberKnife treatment of intraorbital
metastases: a single center experience on 24 lesions.
G. Riva
1
, M. Augugliaro
1
, G. Piperno
1
, A. Ferrari
1
, E.
Rondi
1
, S. Vigorito
1
, R. Orecchia
1
, B.A. Jereczek-Fossa
1
1
Istituto Europeo di Oncologia - IEO, Radiotherapy, MIlan,
Italy
Purpose or Objective
The aim of the study is to evaluate the feasibility, acute
toxicity and symptoms control of CyberKnife (Accuray,
Sunnyvale, CA)-based stereotactic radiotherapy (CBK-SRT)
on intraorbital metastases.
Material and Methods
This retrospective analysis included patients (pts) with
symptomatic metastases located wholly within the orbit.
Palliative radiation treatment was performed using
CyberKnife image-guided technology (using skull-tracking
technique). Gross tumor volume (GTV) volume was
defined on a pre-radiotherapy magnetic resonance
imaging (MRI) with Gadolinium. Treated volumes and
dose-volume histograms (DVHs) are discussed. Acute
toxicity was recorded according to Radiation Therapy
Oncology Group/European Organization for Research and
Treatment of Cancer (RTOG/EORTC) Scale.
Results
Between April 2012 and July 2016, 24 metastases (21 pts,
3 treated bilaterally) underwent CBK-SRT for intraorbital
lesions (10 intraocular, 14 periocular) from different
primary tumors (breast in 13 pts, lung in 3 pts, kidney in 2
pts, lymphoma in 1 pts, thyroid in 1 pts, trunk
leiomyosarcoma in
1
pts).
The median treatment dose was 18 Gy (range, 15-24 Gy)
given over a median of 3 fractions (range, 2-3 fractions)
with a median dose of 6 Gy per fraction (range, 5-10
Gy/fraction). Treated volumes and DVHs are reported in
Table 1.
At the end of the treatment, grade 1 toxicity according to
RTOG/EORTC score was observed in 8 cases. No change in
visual field or loss of vision was documented.
13 lesions of 24 had undergone post-radiotherapy MRI and
after median follow-up of 6 months (range, 2.0-26.5
months) no local recurrence occurred. All of these
patients reported decreasing pre-radiotherapy symptoms
and improvement in quality of life. Longer follow-up
(more than 12 months) is available in 4 lesions with
complete radiological response in all cases.
Conclusion
In our experience, CyberKnife radiotherapy is a well-
tolerated, safe and efficacious technique for palliative
treatment of intraocular and periocular metastases.
EP-1396 Versatis® and focal neuropathic pain in
cancer patients (screening tool)
C. Prieto Prieto
1
, E. López Ramirez
2
1
Hospital Universitario Virgen de las Nieves, Radiation
Oncology, Granada, Spain
2
Oncosur, Oncología Radioterápica, Granada, Spain
Purpose or Objective
Lidocaine 5% patch (L5%P) = (Versatis®) represents a novel
therapeutic approach to neuropathic pain in cancer
patients. The objective of this study is to evaluate its role
in treating acute or chronic focal neuropathic pain (FNP)
in cancer patients, regardless of its causal relationship
with the tumour.
Material and Methods
We collected information from 33 cancer patients with
focal neuropathic pain (FNP) treated with L5%P. Some
interesting data related to L5%P use were analyzed: NP
nature, body areas affected, previous and concomitant
analgesic treatment, time from patch application to
analgesic effect, duration of therapy with L5%P, analgesic
efficacy and adverse reactions. Therapeutic indication
with L5%P was established in all patients using a validated
FNP screening tool (ST) consisting in 4 simple questions.
Results
All patients underwent radiotherapy in our Departments.
66.7% of them (n=22) suffered from FNP related with
cancer and its therapies. In the other 33.3% of cases
(n=11), FNP was not considered related. Potent analgesic
effect of L5%P was observed in 23 cases (69.7%), and
partial effect in 5 cases (15,2%). It represents an 84.9% of
efficacy in our sample. 81.3% of patients did not report
adverse reactions at all. 45.5% of patients achieved pain
control within one week after starting L5%P treatment.
39.4% of patients did not need concomitant analgesic
treatment.
Conclusion